|
 |
|
|
|
|
|
|
|
|
|
|
product pipeline
|
|
|
|
|
OphthalmoPharma’s product pipeline is focused on the development of innovative drugs and medical devices for ophthalmology.
click here to enlarge
Therapeutic Compounds (in development)
- A proprietary water soluble Cyclosporin A and a proprietary water soluble Cyclosporin A prodrug for the treatment of dry eye syndrome (pre-clinical stage)
- Novel formulation and delivery platforms, based on third generation monosubstituted cyclodextrins, designed for the ocular administration of new molecules and new applications of existing molecules for the treatment of:
- Age-related macular degeneration (AMD)
- Glaucoma
- Inflammations
- Eye infections
- Dry eye syndrome
- Preservative for ophthalmic formulations
Medical Device (in late-stage development)
- SOLO®, a pre-loaded intra-ocular lens injector device
Neutraceutical Product (in development)
- Neutraceuticals for slowing the progression of eye diseases
| | |
| | |
|
|
|
|
